NCT04670445View on ClinicalTrials.gov

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

January 23, 2021

Primary Completion Date

March 23, 2023

Study Completion Date

April 30, 2024

Conditions
Stage IV MelanomaAdvanced Lung CancerStage IV Non-Small Cell Lung CancerUnresectable Non-Small Cell Lung CarcinomaUnresectable Stage III Non-Small Cell Lung CancerSmall Cell Lung Cancer Extensive StageStage IV Merkel Cell CarcinomaStage IV Cutaneous Squamous Cell CarcinomaStage IV Basal Cell CarcinomaStage IV Breast CancerStage IV Colorectal CancerStage IV Gastric CancerStage IV Esophageal CancerStage IV Hepatocellular CancerStage IV Renal Cell CarcinomaStage IV Bladder CancerStage IV Head and Neck Squamous Cell CarcinomaStage IV Cervical CancerStage IV Endometrial CancerStage IV MesotheliomaImmunotherapyImmune Checkpoint Inhibitors
Interventions
OTHER

Educational Video and QPL List

The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.

OTHER

Usual Care

Surveys

Trial Locations (1)

02115

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Conquer Cancer Foundation

OTHER

lead

Massachusetts General Hospital

OTHER